Results 31 to 40 of about 35,812 (218)
Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
Nature Communications, 2023 Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival.
Goutam Chakraborty +2 more
doaj +1 more source
An exceptional response to 177LuPSMA undermined by neuroendocrine transformation
Urology Case Reports, 2021 Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). 177Lu-prostate specific membrane antigen (
Pretoria Bilinski, Myles Webb
doaj +1 more source
Neuroendocrine differentiation in prostate cancer – a review [PDF]
Romanian Journal of Military Medicine, 2015 Objectives: This review aims to provide practicing clinicians with the most recent knowledge of the biological nature of prostate cancer especially the information regarding neuroendocrine differentiation.
R. Popescu +6 more
doaj
Neuroendocrine differentiation in prostate cancer [PDF]
The Chinese-German Journal of Clinical Oncology, 2005 Hormonal therapy is an important treatment for advanced/metastatic prostate cancer. But it can induce neuroendocrine (NE) differentiation in prostate cancer cells. These NE cells will secrete manifold neural peptide or hormones which can lead to androgen-independent growth of non-NE tumor cells.
Jingwen Wang, Yang Yao
openaire +2 more sources
Neuroendocrine aspects of prostate oncogenesis [PDF]
Саратовский научно-медицинский журнал, 2010 The prostate cancer is a widespread disease in Russia with high growth rate and high death rate. Active work in discovery of methods of early diagnostics of prostate cancer is carrying out.
P.V. Glybochko, V.M. Popkov
doaj
IJU Case Reports, 2021 Introduction Treatment‐related neuroendocrine prostate cancer, a rare and aggressive malignancy that emerges during androgen deprivation therapy characterized by low serum prostate‐specific antigen concentrations, is challenging to monitor because it is ...
Ryo Kurashina +9 more
doaj +1 more source
Primary neuroendocrine prostate cancer with adrenal gland metastasis
Urology Case Reports, 2022 Primary neuroendocrine differentiation in prostate cancer occurs infrequently and represents a therapeutic challenge at present due to the poor prognosis involved.
Antonio Yaromin Muñoz López +5 more
doaj +1 more source
Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer. [PDF]
Ann MedProstate cancer (PC) is a common male malignancy. Although androgen deprivation therapy (ADT) is standard for advanced PC, many patients develop castration-resistant PC (CRPC), and some progress to neuroendocrine PC (NEPC). This study aims to clarify mechanisms of this transition, especially the role of cancer stem cells (CSCs), and explore therapeutic
Shao B, Zeng Y.
europepmc +4 more sources
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells [PDF]
Endocrine-Related Cancer, 2007 Abstract Neuroendocrine (NE) cells represent a minor cell population in the epithelial compartment of normal prostate glands and may play a role in regulating the growth and differentiation of normal prostate epithelia. In prostate tumor lesions, the population of NE-like cells, i.e., cells exhibiting NE phenotypes and expressing NE ...
Ta-Chun, Yuan +2 more
openaire +2 more sources
FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate
World Journal of Surgical Oncology, 2008 Background FDG PET-CT is generally not suitable for diagnosing prostate cancer because of low glycolysis of the tumor cells. Neuroendocrine differentiation of the prostate cancer is often associated with early visceral metastasis and dismal prognosis ...
Liu Yiyan
doaj +1 more source